Estimation of the direct cost of diabetes in the Arab region

Mediterranean Journal of Nutrition and Metabolism

Volumn 7, Issue 1, 2014, Pages 21-32

  Boutayeb, Abdesslam ^a   Boutayeb, Wiam ^a   Lamlili, Mohamed E N ^a   Boutayeb, Saber ^b  

^a FACULTÉ DES SCIENCES   (Morocco)

^b NATIONAL INSTITUTE OF ONCOLOGY   (Morocco)

Author keywords

Arab countries; Diabetes; Direct cost; Income group; Prevalence

Indexed keywords

GLIBENCLAMIDE; GLICLAZIDE; INSULIN; METFORMIN;

AGE; ARTICLE; CONSULTATION; DIABETES MELLITUS; DRUG COST; EARLY DIAGNOSIS; GENDER; GEOGRAPHIC DISTRIBUTION; HEALTH CARE COST; HEALTH CARE DISPARITY; HOSPITALIZATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LABORATORY TEST; MIDDLE EAST; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION SIZE; PREVALENCE; PRIORITY JOURNAL; PRODUCTIVITY; SOCIAL STATUS; SOCIOECONOMICS; WORLD HEALTH ORGANIZATION;

EID: 84901987408     PISSN: 1973798X     EISSN: 19737998     Source Type: Journal    
DOI: 10.3233/MNM-140002     Document Type: Article

References (55)

1. World Economic Forum. Global Risks 2010; http://www.weforum.org/reports/ global-risks-2010
2. International Diabetes Federation. IDF DIABETES ATLAS fifth edition. IDF 2011, Bressels, Belgium
3. El-Hazmi MA,Warsy A, Al-Swailem A, Al-Swailem A, Sulaimani R. Diabetes mellitus as a health problem in Saudi Arabia. East Mediterr Health J. 1998;4(1):58-67. (Pubitemid 128471025
4. Al-Nuaim AR. Prevalence of glucose intolerance in urban and rural communities in Saudi Arabia. Diabet Med. 1997;14:595-602. (Pubitemid 27298821
5. Al-Nozha MM, Al-Maatouq MA, Al-Mazrou YY, Al-Harthi SS, Arafah MR, Khalil MZ, et al. Diabetes mellitus in Saudi Arabia. Saudi Med J. 2004;25:1603-10. (Pubitemid 39646631
6. Zaoui S, Bíemont C, Meguenni K. Approche ́epid́ emiologique du diabète en milieux urbain et rural dans la ŕegion De Tlemcen (Ouest alǵerien). Cahiers Sant́e. 2007;17(1):15-21
7. Malek R, Belateche F, Laoumiri FS, et al. Prevalence du diabète de type2 et de l'intoĺerance au glucose dans la ŕegion De Śetif (Alǵerie). Diabetes Metabolism. 2001;18:229-53
8. Ministry of Health Algeria. Alg'erie Enqûete STEPS. Technical Report. Ministry of Health Algeria and World Health Organization 2005. http://www.who.int/chp/steps/STEPS Report Algeria.pdf
9. Boutayeb A, Boutayeb S. The burden of NCDs in Developing countries. International Journal for Equity in Health. 2005;4:2
10. World Health Organisation. The cost of diabetes 2010. http://www.who.int/mediacentre/factsheets/fs236/en/
11. American Diabetic Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care. 2008;31(3):596-615
12. Canadian Diabetes Association. An economic tsunami: The cost of diabetes in Canada 2010. http://www.diabetes.ca/documents/getinvolved/ FINAL Economic Report.pdf
13. Diabetes UK. Diabetes in the UK 2010: Key statistics on Diabetes. http://www.diabetes.org.uk/Documents/Reports/Diabetes in the UK 2010.pdf
14. Barcelo A, Aedo C, Rajpathak S, Robles S. The cost of diabetes in Latin America and the Caribbean. Bulletin of the World Health Organization. 2003;81(1):19-27. (Pubitemid 36168649
15. Kirigia JM, Sambo HB, Sambo LG, Barry SP. Economic burden of diabetes in the WHO African region. BMC International Health and Human Rights. 2009;9:6. http://www.biomedcentral.com/1472-698X/9/8
16. Kim TH, Chun KH, Kim HJ. Direct Medical Costs for Patients with Type 2 Diabetes and Related Complications: A Prospective Cohort Study Based on the Korean National Diabetes Program. Journal of Korean Medical Sciences. 2012;27(8):876-82
17. Al-Maskari F, El-Sadig M, Nagelkerke N. Assessment of the direct medical costs of diabetes mellitus and its complications in the United Arab Emirates. BMC Public Health. 2010;10:679. http://www.biomedcentral.com/content/pdf/1471- 2458-10-679.pdf
18. World Health Organisation. WHO Global Health expenditure Atlas. World Health Organisation, Geneva 2010. http://www.who.int/ nha/atlas.pdf
19. Novo Nordisk. Novo Nordisk solution for diabetes pandemic in MENA region. www.novonordisk.com
20. Kingdom of Bahrain Ministry of Health. National Non-communicable Diseases Risk Factors Survey 2007. Ministry of Health, Bahrain 2009. http://www.who.int/chp/steps/2007 STEPS Survey Bahrain.pdf
21. Al-Mahroos F, Mckeigue PM. High prevalence of diabetes in Bahrainis: Association with ethnicity and raised plasma cholesterol. Diabetes Care. 1998;6:936-42. (Pubitemid 28488785
22. Ellabany E, Abel-Nasser M. Community based survey study on non-communicable diseases and their risk factors in Egypt, 2005-2006. Technical Report. Ministry of Health and Population, and WHO. Egypt 2006. http://www.who.int/chp/steps/STEPS Report Egypt 2005-06.pdf
23. Mansour AA,Wanoose HL, Hani I, Abed-Alzahrea A,Wanoose HL. Diabetes screening in Basrah, Iraq: A population-based cross-sectional study. Diabetes Research and Clinical Practice. 2008;79:147-50
24. Iraq Ministry of Health. 2006. Chronic non-communicable diseases risk factor survey in Iraq. Technical Report. Iraq Ministry of Health and Ministry of planning and Development Cooperation, and World Health Organization 2009. http://www.who.int/chp/steps/ IraqNorthernGovernoratesSTEPSReport2003.PDF
25. Ajlouni K, Khader YS, Batieha A, Ajlouni H, El-Khateeb M. An increase in prevalence of diabetes mellitus in Jordan over 10 years. Journal of Diabetes and Its Complications. 2008;22:317-24
26. Ajlouni K, Jaddou H, Batieha A. Diabetes and impaired glucose tolerance in Jordan: Prevalence and associated risk factors. J Intern Med. 1998;244:317-23. (Pubitemid 28473995
27. Zindah M, Belbeisi A,Walke H, Mokdad AH. Obesity and diabetes in Jordan: Findings from the behavioural risk factor surveillance system, 2004. Preventing Chronic Diseases. 2008;5(1):A17. http://www.cdc.gov/pcd/issues/2008/jan/06 0172.htm
28. Abdella N, Al Arouj M, Al Nakhi A, Al Assoussi A, Moussa M. Non-insulin-dependent diabetes in Kuwait: Prevalence rates and associated risk factors. Diabetes Research and Clinical Practice. 1998;42(3):187-96. (Pubitemid 29009780
29. Kadiki OA, Roaeid RB. Prevalence of diabetes mellitus and impaired glucose tolerance in Benghazi Libya. Diabetes Metabolism. 2001;27(6):647-54. (Pubitemid 34007859
30. Tazi MA, Abir-Khalil S, Chaouki N, Cherqaoui S, Lahmouz F, Srairi SE. Prevalence of the main cardiovascular risk factors in Morocco: Results of a National Survey 2000. J Hypertens. 2000;21:897-903
31. Ramdani N, Vanderpas J, Boutayeb A, Meziane A, Hassani B, Zoheir J, Legssyer A, Aziz M, Mekhfi H, Bnouham M, Ziyyat A. Diabetes and obesity in the Eastern Morocco. Mediterranean Journal of Nutrition and Metabolism. 2012;5:149-55
32. Asfour MG, Lambourne A, Soliman A, Al-Behlani S, Al-Asfoor D, Bold A, Mahtab H, King H. High Prevalence of Diabetes Mellitus and Impaired Glucose Tolerance in the Sultanate of Oman: Results of the 1991 National Survey. Diabet Med. 1995; 12:112-25
33. Al-Lawati JA, Al Riyami AM, Mohammed AJ, Jousilahti P. Increasing prevalence of diabetes mellitus in Oman. Diabetic Medicine. 2002;19(11):954-57. (Pubitemid 35356923
34. Al-Moosa S, Allin S, Jemiai N, Al-Lawati J, Mossialos E. Diabetes and urbanization in the Omani population: An analysis of national survey data. Population Health Metrics. 2006;4:5
35. Bener A, Zirie M, Janahi IM, Al-Hamag A, Musallam M, et al. Prevalence of diagnosed and undiagnosed diabetes mellitus and its risk factors in a population based study of Qatar. Diabetes Research and Clinical Practice. 2009;84:99-106
36. Ministry of Health KSA and WHO-EMRO. Non Communicable Diseases Risk Factors. Technical Report. Saudi Arabia 2005. http://www.who.int/chp/steps/2005 SaudiArabia STEPS Report EN.pdf
37. Ministry of Health of Syria and WHO. Non communicable Diseases Risk Factors Survey in Syria http://www.who.int/chp/steps/Syrian ArabRepublicSTEPSReport.PDF
38. Bouguerra R, Alberti H, Salem LB, Rayana CB, Atti JE, Gaigi S, Slama CB, Zouari B, Alberti K. The global diabetes pandemic: The Tunisian experience. European Journal of Clinical Nutrition. 2007;61(2):160-5
39. Saadi HS, Carruthers G, Nagelkerke N, Al-Maskari F, Afandi B, Reed R, et al. Prevalence of diabetes mellitus and its complications in a population-based sample in Al-Ain, United Arab Emirates. Diabetes Research and Clinical Practice. 2007; 78:369-77. (Pubitemid 350030313
40. Malik M, Bakir A, Abi Saab B, Roglic G, King H. Glucose intolerance and associated factors in the multi-ethnic population of the United Arab Emirates. Diabetes Research and Clinical Practice. 2005;69:188-95. (Pubitemid 40943485
41. WHO and UAE Ministry of Health. The Emirates National Diabetes Study & Screening for Coronary Artery Disease Risk Factors. United Arab Emirates 2009. http://www.unitedhealthgroup.com/news/rel2010/UNH WorkingPaperDiabetesUAE. pdf
42. Al-Habori M, Al-Mamari M, Al-Meeri A. Type II diabetes Mellitus and impaired tolerance inYemen: Prevalence, associated with metabolic changes and risk factors. Diabetes Research and Clinical Practice. 2004;65:275-81. (Pubitemid 39141184
43. International Diabetes Federation. Report on the International Insulin and Diabetes Supplies Survey on cost and Availability, Bressels, 2006
44. WHO and HAI. Measuring medicine prices, availability, affordability and price components 2d Edition. World Health Organization and Health Action International 2008. http://www.who.int/medicines/areas/access/OMS Medicine prices.pdf
45. International drug price indicator guide. Management Sciences for Health, Washigton DC, 2006
46. Cameron A, Ewen M, Ross-Degnan D, Boll D, Laining R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: A secondary analysis. Lancet. 2009;373:240-49
47. Agence Nationale d'Assurance Maladie. M'edicaments et prix. Available at http://www.assurancemaladie.ma/anam.php?. id espace=6&id srub=19&ir=2
48. Khowaja LA, Khuwaja AK, Cosgrove P. Cost of diabetes care in out-patient clinics of Karachi, Pakistan. BMC Health Services Research. 2007;7:189
49. Boutayeb A, Lamlili M, Boutayeb W, Maamri A, Ziyyat A, Ramdani N. The rise of diabetes prevalence in the Arab region. Open Journal of Epidemiology. 2012;2:55-60
50. Boutayeb A. Reader's comments: Discussion of estimation parameters. BMC International Health and Human Rights 2012 http://www.biomedcentral.com/1472- 698X/9/6/comments
51. UKPDS (U.K. Prospective Diabetes Study) Group. Intensive Blood-Glucose Control with Sulphonylureas or Insulin Compared with Conventional Treatment and Risk of Complications in Patients with Type 2 Diabetes (UKPDS 33). Lancet. 1998;352(9131):837-53
52. Venkat KM, Zhang NP, Kanaya AM,Williams DE, Engelgau MM, Imperatore G, Ramachandran A. Diabetes: The Pandemic and Potential Solutions. In Disease Control Priorities in Developing Countries, chapter 30. Jamison DT et al editors. Washington (DC): World Bank, 2006
53. Boutayeb A. The Double burden of communicable and non-communicable diseases in Developing countries. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2006;100(3):191-9. (Pubitemid 43091815
54. Bjork S. The cost of diabetes and diabetes care. Diabetes Research and Clinical Practice. 2001;54:S13-8
55. World Health Organisation. The cost of diabetes. World Health Organisation, Geneva, 2012. http://www.who.int/mediacentre/factsheets/ fs236/en/